复方苦参注射液联合羟考酮治疗胃癌晚期癌痛的临床研究

Clinical study of Fufang Kushen injection combined with oxycodone in treatment of advanced cancer pain of gastric cancer

目的 分析复方苦参注射液联合羟考酮治疗对胃癌晚期癌痛患者临床效果。方法 以2018年5月至2020年5月间南阳医学高等专科学校第三附属医院收治的108例胃癌晚期患者为研究样本,将其平均随机分为两组,即对照组(54例)和联合组(54例),对照组采用羟考酮治疗,联合组在进行羟考酮治疗的同时采用复方苦参注射液治疗。观察比较两组患者治疗前后癌痛缓解程度和生活质量的变化情况,记录不良反应发生情况。结果 两组患者治疗后NRS评分与治疗前相比明显降低,差异存在统计学意义(联合组P=0.000,对照组P=0.000)。分别对治疗前、治疗后两组NRS评分进行对比,治疗前差异不具备统计学意义(P>0.05),治疗后联合组NRS评分(1.93±0.62)低于对照组(3.88±0.87),差异具备统计学意义(P=0.000)。治疗前,两组患者生理健康、精力表现、情绪角色及社会功能差异不具备统计学意义(P>0.05),治疗后联合组生理健康、精力表现、情绪角色、社会功能分别为(69.99±1.61)分、(62.91±1.63)分、(64.06±2.73)分、(65.45±2.14)分均高于对照组(61.57±0.89)分、(61.02±0.58)分、(58.24±1.95)分、(63.33±1.28)分,差异具备统计学意义(P=0.000)。联合组与对照组患者治疗过程中多汗、头晕乏力、便秘、排尿困难及恶心呕吐发生情况均不具备统计学意义(P>0.05)。结论 复方苦参注射液联合羟考酮治疗可有效降低胃癌晚期患者癌痛发生,同时可提高免疫系统功能,改善生活质量。

Objective To analyze the clinical effect of Fufang Kushen injection combined with oxycodone in the treatment of patients with advanced cancer pain of gastric cancer. Methods Totally 108 patients with advanced gastric cancer treated in The Third Affiliated Hospital of Nanyang Medical College from May 2018 to May 2020 were taken as the study samples and randomly divided into two groups: control group(54 cases) and combined group(54 cases). The control group was treated with oxycodone, and the combined group was treated with Fufang Kushen injection at the same time. The changes of cancer pain relief and quality of life of patients in both groups were observed and compared before and after treatment, and the occurrence of adverse reactions was recorded. Results The NRS score of both groups after treatment was significantly decreased than that before treatment, and the difference was statistically significant(P=0.000 in the combined group and P=0.000 in the control group). The NRS scores of both groups before and after treatment were compared, and there was no statistical significant difference before treatment(P>0.05), after treatment, the NRS score of the combined group(1.93±0.62) was significantly lower than that of the control group(3.88±0.87), and the difference was statistically significant(P=0.000). Before treatment, there was no statistical significant difference in physical health, energy performance, emotional role and social function of patients in both groups(P>0.05), after treatment, the scores of physical health, energy performance, emotional role and social function in the combined group were(69.99±1.61),(62.91±1.63),(64.06±2.73) and(65.45±2.14) respectively, which were significantly higher than those in the control group(61.57±0.89),(61.02±0.58),(58.24±1.95) and(63.33±1.28), and the difference was statistically significant(P=0.000). There was no statistical significant difference in the incidence of hyperhidrosis, dizziness and fatigue, constipation, dysuria, nausea and vomiting of patients in the combined group and the control group during treatment(P>0.05). Conclusion Fufang Kushen injection combined with oxycodone can effectively reduce the occurrence of cancer pain in patients with advanced gastric cancer, enhance immune function and improve the quality of life at the same time.